|
|
 David Anstice
David W. Anstice, President, Human Health, is responsible for the Japan, Latin America, Canada, Australia, and New Zealand human health pharmaceutical businesses of Merck & Co., Inc., a world leader in the discovery, development, manufacture and marketing of human health products. He is also responsible for Merck’s joint ventures with Schering-Plough. His most recent assignment was President, Human Health, The Americas.
From September 1994 through December 2002, he was responsible for Merck’s human health businesses for North America, including direct responsibility for the U.S. market as President, U.S. Human Health. In January 1997, Mr. Anstice’s responsibilities were expanded to include the Latin American group. Mr. Anstice was promoted to the position of President, Human Health, U.S./Canada in September 1994 from his preceding assignment as President, Human Health Europe.
An Economics graduate of the University of Sydney in Australia, Mr. Anstice joined Merck in 1974 in Australia. Mr. Anstice serves as a Member, Board of Directors, BIO (Biotechnology Industry Organisation), Washington, DC. Other professional activities Member, Board of Trustees, University of the Sciences in Philadelphia, Philadelphia, PA; Member, Advisory Board of Managers, Morris Arboretum, Philadelphia, PA; Member, CEO Council for Growth, Philadelphia, PA; Chairman, Board of the University of Sydney USA Foundation; and Member, Corporate Advisory Council, The National Alliance for Hispanic Health.
|
|
 Karen Day
Born in Melbourne, Karen Day did not remain in Australia long - after completing her PhD training at the Walter and Eliza Hall Institute of Medical Research and the University of Melbourne, she moved to a research position at the Papua New Guinea Institute of Medical Research. Whilst working in Papua New Guinea, she was overwhelmed by the poverty and disease she saw on a daily basis. "My first reaction was to become a doctor," she says. "Then I stepped back and saw that as a researcher in public health, I could have an impact on a much larger population." This quest to make an impact led her to the UK to learn more about epidemiology and public health - she was a researcher at London's Imperial College for three years and then moved to a lecturer’s post at University of Oxford. She was appointed Fellow at Hertford College, becoming one of the few women "dons" in science at Oxford. She was at University of Oxford from 1994 to 2003. During this time she was promoted to Professor, and she became an Emeritus Fellow of Hertford College after her move to New York University in 2004.
Today, Professor Day is the Chair of Medical Parasitology, Professor of Medicine, Director of the Institute for Urban and Global Health at NYU School of Medicine as well as the Co-Director of the new multi-school Masters Program in Global Public Health at New York University. She is also an Ellison Senior Scholar in Global Health. She is actively involved in global health research, training and advocacy both at NYU and beyond. She is passionate about science and how it can be used to combat global health issues. She Chairs the Department of Medical Parasitology with the mission to improve control of neglected disease such as malaria, sleeping sickness and leishmaniaisis. Her own 9 member research group aims to understand the transmission of malaria. The group takes laboratory findings, especially genomics, to the field to investigate the epidemiology of malaria as well as taking observations from the field to the laboratory to identify molecular mechanisms of parasite biology.
Dr Day has worked extensively in Papua New Guinea, Asia and Africa. Her research integrates the disciplines of epidemiology, immunology, molecular parasitology, genomics, bioinformatics and genetics in population based studies to achieve a better understanding of infectious disease control. "The problems in global health are complex. You can't come at them from just one direction, whether it is medicine, science or policy. We have to integrate many disciplines to get results," she says. She has mentored more than 20 PhD and postdoctoral students during her career and is a strong believer in producing scientists who understand all of the dimensions of their work, including social and political aspects of malaria research. Professor Day is also an expert on higher education, having experience of UK, USA and Austalian universities.
|
|
 Peter Farrell
Peter C. Farrell, PhD. DSc., is the Founder of the company and has been Chairman and Chief Executive Officer of ResMed since 1989. He was previously Vice President, R&D with Baxter Healthcare (1984-89) and Foundation Director of University of New South Wales Graduate School for Biomedical Engineering where he remains a Visiting Professor.
He has over 20 years’ consulting and executive experience in the medical device industry. He is a Fellow of several professional bodies, including the Australian Institutes of Management and Company Directors. Dr. Farrell is Vice Chair of the Executive Council of the Division of Sleep Medicine at Harvard Medical School and serves on the Board of Trustees at UCSD.
In 1994, the Australian Institution of Engineers awarded Dr. Farrell the honor of National Professional Engineer of the Year, and in 1997, he received the David Dewhurst Award (Biomedical Engineer of the Year) from the same institution. He was also named San Diego Entrepreneur of the Year for Health Sciences in 1998 and Australian Entrepreneur of the Year for 2001.
Dr. Farrell holds bachelor and masters degrees in chemical engineering from the University of Sydney and the Massachusetts Institute of Technology respectively, a PhD in bioengineering from the University of Washington in Seattle, and a DSc from the University of New South Wales for research related to dialysis and renal medicine.
|
|
 Richard R. Goodmanson
Richard R. Goodmanson is executive vice president and chief operating officer of DuPont. Richard oversees all of DuPont’s activities. One of the five growth platforms at DuPont, Agriculture & Nutrition, is focused intensively on biotechnology. Bio-based materials division is focused on the use of biotechnology in materials science.
Mr. Goodmanson was president and chief executive officer of America West Airlines from 1996 to 1999.
Mr. Goodmanson received a degree in civil engineering from the Royal Military College of Australia, bachelor degrees in both commerce and economics from the University of Queensland, and a master of business administration degree from Columbia University.
|
 Russell J. Howard, Ph.D.
Russell J. Howard, Ph.D., is CEO and co-founder of Maxygen, Inc., based in Redwood City CA and Copenhagen, ºDenmark, a public company (NASDAQ: MAXY) dedicated to discovery and development of human therapeutics.
Maxygen has primary focus on protein pharmaceuticals with partnered development programs on alpha-interferon (Roche) and gamma-interferon (Intermune) and internal programs on beta-interferon and GCSF.
By leverage of its proprietary technologies, Maxygen created a wholly-owned agricultural biotechnology business, Verdia, recently sold to Dupont, and a venture-financed fine chemicals business, Codexis, in which Maxygen retains majority ownership.
Maxygen was spun-off from GlaxoWellcome in 1997, went public in 1999, completed a secondary offering in early 2000, and acquired a Danish protein pharmaceuticals company in 2000.
|
|
 Ismail Kola, Ph.D. (Med)
Senior Vice President, Basic Research & Site Head for Basic Research, Rahway, Merck Research Laboratories with responsibility for therapeutic areas: Atherosclerosis, Diabetes/Obesity, Infectious Diseases, Immunology/Rheumatology, Animal Pharmacology, and Basic and Medicinal Chemistry. The reporting line comprises 900 people and has a budget of approximately US $225 million. The site has delivered 11 preclinical candidates (PCC’s) with approximately 70% of these being novel mechanism compounds.
Dr Kola is an Adjunct Professor of Medicine at Washington University (St. Louis, MO) and at Monash University, Australia, as well as a Foreign Adjunct Professor at the Karolinska Institute, Stockholm, Sweden. He is a member of the Board of Directors of EraGen Biotech, Wisconsin, U.S.A. (September 2000-current), Promega Corp., Wisconsin, U.S.A. (October 2002-current) and the Aspen Cancer Conference.
Dr. Kola has authored or co-authored over 130 publications, many of which have been published in the most eminent scientific journals such as Nature, Nature Genetics, Proceedings of the National Academy of Sciences U.S.A, EMBO J, and he is a named inventor on twelve patents. He has been the recipient of several international prizes, scholarships and awards for his research work.
He graduated B.Sc. (University of South Africa); B.Pharm cum laude (Rhodes University, South Africa); and Ph.D. (Med) (University of Cape Town).
|
|
 Andrew Liveris
Andrew N. Liveris is Chief Executive Officer of The Dow Chemical Company, Midland, Michigan. He was named to the Board of Directors in February 2004. Liveris’ 28-year Dow career has spanned manufacturing, sales, marketing, new business development and management. He joined Dow in 1976 in Melbourne, Australia, and held various production, project engineering and marketing positions in Australia, Hong Kong and the U.S.
In 2000, Liveris was appointed president of Performance Chemicals Business Group, a $5 billion portfolio that brought together specialty chemical businesses from several acquisitions, including ANGUS Chemical, Hampshire Chemical, Union Carbide, Ascot Plc and, the acrylics business of Celanese AG. These businesses serve diverse markets such as coatings, pharmaceuticals, household and personal care products, water purification, and pulp and paper.
Liveris was instrumental in the formation of Elemica, the groundbreaking chemicals e-commerce marketplace, and served as founding co-chairman of Elemica’s Board of Directors in 2000 and 2001. He is a member of the board and the executive committee of the OPTIMAL Group of Companies, a set of joint ventures in Malaysia that serve as Dow’s first major integrated petrochemical facility in Asia.
Liveris graduated with first-class honors with a bachelor’s degree in Chemical Engineering from the University of Queensland, Brisbane, Australia, and received the University Gold Medal the year he graduated – the university’s highest honor. He is a corporate member of The Institute of Chemical Engineers.
|
 Bridget Ogilvie, AC, DBE, ScD, FRS
Bridget Ogilvie took her first degree in agricultural science (BRurSc) from the University of New England in Australia in 1960. She obtained her doctoral degrees from the University of Cambridge (PhD in 1963, ScD in 1981) for research in parasite immunology. Her career has had three phases, initially as a scientist undertaking research on the staff of the Medical Research Council, then as a staff member of an organisation that funds medical research, The Wellcome Trust, now involved in science and education through a number of non-executive positions.
For 17 years she was a member of the staff of the UK Medical Research Council at the National Institute for Medical Research, Mill Hill, London. In those years, she undertook research on the immune response to parasitic infections. She travelled widely in both the developed world and the tropics in pursuit of her research interests and as an advisor for bodies such as the World Health Organisation. From 1985 to 1991, she was a Visiting Professor at the Imperial College of Science, Technology and Medicine in London. She is now a Visiting Professor at University College, London.
She joined the staff of the Wellcome Trust in 1979 where her first post was a half-time appointment as coordinator of its tropical medicine programme, whilst still running her research group at the NIMR. In 1981 she joined the staff on a full-time basis as Deputy Secretary and Assistant Director. She was promoted to Deputy Director (Science) in 1984 and then to Director (Science Programmes) in 1989, with responsibility for the science funding activities of the Trust overall. At that time she also took a particular interest in schemes for the career development of scientists and medical graduates, and in the veterinary programme of the Trust. In October 1991, she was appointed Director (Chief Executive) of the Trust and retired from this position at the end of June, 1998.
She has received a number of honorary memberships, fellowships and doctorates from scientific societies and academic institutions in the UK and abroad. Following her retirement from the staff of The Wellcome Trust, she is currently occupying herself with a number of non executive posts in science and education. She is a Trustee of Cancer Research UK, non executive Director of AstraZeneca plc, and Chairman of Medicines for Malaria Venture, Association of Medical Research Charities, the Lister Institute, together with many other non executive interests.
On January 26, 2007, Dame Bridget Ogilvie was awarded the ‘Companion of the Order of Australia’, Australia’s highest distinguished service award, with the citation: “For service to science in the field of biomedical research, particularly related to veterinary and medical parasitology, and through support for research funding to improve global health."
|
|
 Gary W. Pace, Ph.D.
Gary W. Pace, Ph.D., is currently co-founder, Chairman and CEO of QRxPharma Pty Ltd a development stage biopharmaceutical company, a Visiting Scientist at the Massachusetts Institute of Technology (MIT) and Adjunct Professor at the University of Queensland. He is also a Director of ResMed (NYSE:RMD), Transition Therapeutics Inc. (CDNX:TTH), Celsion Corp (AMX:CLN), Peplin Ltd (ASX: PEP) and Protiveris Inc.
From 1995 to 2001 Dr. Pace was President and CEO of RTP Pharma and from 2000 to 2002 Dr. Pace was co-founder, Chairman and CEO of Waratah Pharmaceuticals Inc., a spin-off company from RTP Pharma. From 1993 to 1994, he was the founding President and Chief Executive Officer of Transcend Therapeutics Inc. (formerly Free Radical Sciences Inc.), a biopharmaceutical company. From 1989 to 1993, he was Senior Vice President of Clintec International, Inc., a Baxter/Nestle joint venture and manufacturer of clinical nutritional products.
In 1996 he also a co-founded CTOUR A/S developing environmental technologies for off-shore oil production. Dr. Pace holds a B.Sc. with honors from the University of New South Wales and a Ph.D. from MIT. He is a Fellow of the Australian Academy for Technological Sciences and Engineering and has published 50 papers and patents.
In 2003 he was awarded a Centenary Medal by the Australian Government for service to Australian society in research and development.
|
 Richard Pestell, M.D. Ph.D, FRACP
Dr. Pestell completed his M.D. (1981) and Ph.D. degrees in Australia. He undertook post doctoral and clinical training in Hematology/Oncology and Endocrinology. As the single Australian recipient of the Royal Australian College of Physicians Winthrop traveling scholar and Neil Hamilton Fairley Scholar (1991-1994) he continued research at Harvard University and served as Clinical fellow at Massachusetts General Hospital. He was Division Chair Albert Einstein College of Medicine in New York, and Director of the Lombardi Comprehensive Cancer Center at Georgetown University. Dr. Pestell currently is the Director of the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia and Chairman of the Department of Cancer Biology. He also serves on a number of boards at Thomas Jefferson.
Dr. Pestell has authored more than 220 original publications and book chapters and more than 150 published abstracts. His papers have been published in outstanding journals including Cell, Science, Nature Medicine, Molecular Cell and EMBO J. His work is highly cited. In March 2002 he was ranked first in the World for increase in total scientific impact in Biology and first in the world for Biochemistry (ISI). Dr Pestell is funded (total grant support of $31M) as the Principal Investigator of 5 RO1 grants and PI of the Kimmel Cancer Center CCSG grant.
He has received a number of awards for his scientific discoveries in breast and prostate cancer including elected membership to the American Society of Clinical Investigators, the Irma T. Hirschl Weil Caulier Career Scientist Award, Diane Belfer Faculty Scholar in Cancer Research, the Pfeiffer Award, and elected membership to the Editorial Academy of the International Journal of Oncology. Dr Pestell serves as a reviewer for 11 funding agencies and has been an active member of NIH study sections (RO1, SPORES, Cancer Centers, Program projects), currently serving as a permanent member of TCB. He has served as study section chair for the Susan Komen Breast Cancer Foundation. He serves as scientific advisory board member to Cancer Centers and Funding agencies. Dr Pestell has been a reviewer for 18 distinct scientific journals and is currently an active editorial board member of 6 journals including J. Biol. Chem . Cancer Res., and Int. J. of Oncology.
Dr. Pestell’s major contributions are to the area of cell-cycle control and targeted cancer therapies. These include the discovery that cyclins are direct transcriptional targets of oncogenic and tumor suppressor signals and that cyclin expression is rate-limiting for oncogene-induced tumor growth in vivo. His laboratory established this as a general mechanisms of oncogenic signaling and showed that the cyclins physically interact with nuclear receptors and tumor suppressors providing novel targets for cancer therapies. He showed that nuclear receptors are acetylated, and that this event is rate-limiting in hormone signaling and growth control- thus a new target for cancer therapy. He demonstrated that this was a general mechanism conserved among nuclear receptors that affect diverse biological processes. His laboratory pioneered the application of tissue-specific inducible transgenics and the development of gene-targeted and transgenic mice providing superior model of human cancer. His patent of light activated gene therapy, which allows single cell targeting of a payload, is broad including all genes in the human genome.
|
|
 Maurice Renshaw
A native of Australia, Mr. Renshaw received a Bachelor of Pharmacy degree from Sydney University and joined Parke-Davis-the prescription medicine and over-the-counter healthcare division of Warner-Lambert-in Australia in 1974. He rapidly advanced through a series of marketing and general management positions in several countries with responsibility for consumer products and prescription pharmaceuticals in Asia, Europe and the Americas.
From 1996 to June 2000, Mr. Renshaw served as President of Parke-Davis USA; in1998, Warner-Lambert appointed him as Corporate Vice President. During this four-year period, he led the Warner-Lambert pharmaceutical business to unprecedented growth of over 500% to $6 billion and was responsible for the successful launch of Lipitor, the world’s leading cholesterol-lowering medicine and the largest-selling pharmaceutical of any kind.
When Pfizer bought Warner-Lambert in 2000, Renshaw was asked to turn around the struggling global consumer health-care unit, which at the time had sales growth of between 1% and 2% a year. Now, after aggressively launching new products such as Listerine PocketPaks, sales are growing 8% annually.
Maurice Renshaw retired from Pfizer in 2004 and was recently appointed to the Board of Directors of CSL.
|
 Dr. Bruce Stillman, Ph.D.
Dr. Bruce Stillman is President and Chief Executive Officer of Cold Spring Harbor Laboratory on the north shore of Long Island in New York. A native of Australia, he obtained a Bachelor of Science degree with honors at Sydney University and a Ph.D. at the John Curtin School of Medical Research at the Australian National University. He joined Cold Spring Harbor Laboratory as a Postdoctoral Fellow in 1979 and has been at the Laboratory ever since. Dr. Stillman has been Director of the Cancer Center at Cold Spring Harbor Laboratory since 1992, a position he still holds.
In 1994, he succeeded Dr. James D. Watson as Director of Cold Spring Harbor Laboratory was appointed President in 2003. Dr. Stillman has received a number of honors including election as a Fellow of The Royal Society in 1993. In 1994, Dr. Stillman was awarded the Julian Wells Medal (Australia) and in 1995 was appointed an Officer of the Order of Australia (AO) for service to scientific research in the field of molecular biology in 1999. Dr. Stillman was elected in 2000 to the U.S. National Academy of Sciences. In 2004, Dr. Stillman was awarded the Alfred P. Sloan, Jr. Prize from the General Motors Cancer Research Foundation with Dr. Thomas Kelly. He has also received three honorary doctorates.
Dr. Stillman is a member of the Medical Advisory Board of the Howard Hughes Medical Institute and advises a number of other research organisations including the M.I.T. Cancer Center, Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia and the New York Biotechnology Association.
|
|
 Peter Turner
As President of ZLB Behring L.L.C., Peter Turner brings over 34 years of leadership experience to the company, including over 20 years of plasma fractionation research and development, production, engineering and business development expertise.
Most recently, Mr. Turner contributed to the successful acquisition of Aventis Behring to form ZLB Behring L.L.C. Prior to this position, Mr. Turner served as Chief Executive Officer and President of ZLB Bioplasma AG and ZLB Bioplasma Inc. (the ZLB Bioplasma Group) from July 2000 to March 2004.
During this time, he was also responsible for the integration of ZLB and Nabi Plasma Collection Centres into the CSL Group. From 1996 to 2000, Mr. Turner served as General Manager of CSL Bioplasma (a business unit of CSL Limited).
As General Manager, he supervised marketing, manufacturing and quality operations, research & development and engineering activities. Prior to General Manager, Mr. Turner served as Operations Manager and Plasma Products Project Director.
Mr. Turner is Chairman of the Plasma Protein Therapeutics Association, and holds a B.Sc. in chemistry, biochemistry and microbiology from the University of Melbourne and a MBA from Royal Melbourne Institute of Technology.
|
|
